Moving Away from Injections: How the New Pills Work
Currently, the most effective medical weight loss treatments are administered via a weekly subcutaneous injection. While highly successful, scientists have been working to formulate these complex, appetite-regulating proteins into a stable, daily tablet that can survive the digestive system.
Two major developments are leading this shift:
1. High-Dose Oral Semaglutide (Novo Nordisk)
Novo Nordisk, the creators of Wegovy, developed a high-dose oral version of semaglutide specifically designed for weight management. The MHRA licensed this as the Wegovy pill in the UK on 11 June 2026. Trial results from the OASIS programme have shown significant weight reductions that rival the injectable formulation.
2. Orforglipron (Eli Lilly)
Eli Lilly is developing Orforglipron, a non-peptide GLP-1 receptor agonist. The primary advantage of Orforglipron is its user-friendly design. While some current oral GLP-1s require strict fasting before and after taking the tablet, Orforglipron is being engineered to have fewer dietary restrictions, making it an incredibly convenient daily option for sustained weight management.
What This Means for Patients
The introduction of these oral medications will significantly broaden the options available for treating obesity.
- No more needles: An accessible alternative for those who experience anxiety around injections.
- Travel and storage: Pills are generally easier to travel with and store compared to injectable pens, which often require refrigeration before use.
- Tailored care: More options allow clinicians to better personalise your treatment plan based on your lifestyle, preferences, and clinical needs.
It is important to note that, just like current treatments, these new oral medications will be most effective when used alongside a comprehensive lifestyle plan, including a balanced diet and regular physical activity.
Check your eligibility for the Wegovy Pill
Following MHRA licensing on 11 June 2026, you can pre-order the Wegovy pill through PrivateDoc now. Complete a free online consultation and our clinicians will assess whether oral semaglutide is appropriate for you.
What to Do in the Meantime?
If you are already on a weight loss journey, you do not need to wait for these new pills to take control of your health.
Current treatments like Wegovy and Mounjaro remain highly effective, safe, and available. If you are a current PrivateDoc patient, please continue your prescribed treatment as normal. When you wish to explore the MHRA-licensed Wegovy pill, our clinical team can help you transition safely if it is the right clinical choice for you.
If you are looking to start your weight loss journey today, you can explore our current, clinically proven treatments and see if you are eligible below.
Disclaimer & Summary
This article is for informational purposes only and does not replace individual medical advice. Availability and approvals of pipeline medications vary by country and are subject to regulatory review by the MHRA. Always consult a qualified healthcare professional before starting or changing any medical treatment.
2026 is poised to bring greater flexibility to weight management. By staying informed and working with registered UK clinicians, you can ensure your weight loss journey is safe, effective, and tailored entirely to you.
